Base de dados : MEDLINE
Pesquisa : B04.280.650.160.100.149 [Categoria DeCS]
Referências encontradas : 109 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 11 ir para página                         

  1 / 109 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28947539
[Au] Autor:Liu F; Niu Q; Fan X; Liu C; Zhang J; Wei Z; Hou W; Kanneganti TD; Robb ML; Kim JH; Michael NL; Sun J; Soong L; Hu H
[Ad] Endereço:Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555.
[Ti] Título:Priming and Activation of Inflammasome by Canarypox Virus Vector ALVAC via the cGAS/IFI16-STING-Type I IFN Pathway and AIM2 Sensor.
[So] Source:J Immunol;199(9):3293-3305, 2017 Nov 01.
[Is] ISSN:1550-6606
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Viral vectors derived from different virus families, including poxvirus (canarypox virus vector ALVAC) and adenovirus (human Ad5 vector), have been widely used in vaccine development for a range of human diseases including HIV/AIDS. Less is known about the mechanisms underlying the host innate response to these vectors. Increasing evidence from clinical vaccine trials testing different viral vectors has suggested the importance of understanding basic elements of host-viral vector interactions. In this study, we investigated the innate interactions of APCs with two commonly used HIV vaccine vectors, ALVAC and Ad5, and identified AIM2 as an innate sensor for ALVAC, triggering strong inflammasome activation in both human and mouse APCs. Microarray and comprehensive gene-knockout analyses (CRISPR/Cas9) identified that ALVAC stimulated the cGAS/IFI16-STING-type I IFN pathway to prime AIM2, which was functionally required for ALVAC-induced inflammasome activation. We also provided evidence that, in contrast to ALVAC, the Ad5 vector itself was unable to induce inflammasome activation, which was related to its inability to stimulate the STING-type I IFN pathway and to provide inflammasome-priming signals. In preconditioned APCs, the Ad5 vector could stimulate inflammasome activation through an AIM2-independent mechanism. Therefore, our study identifies the AIM2 inflammasome and cGAS/IFI16-STING-type I IFN pathway as a novel mechanism for host innate immunity to the ALVAC vaccine vector.
[Mh] Termos MeSH primário: Adenoviridae/imunologia
Células Apresentadoras de Antígenos/imunologia
Vírus da Varíola dos Canários/imunologia
Proteínas de Ligação a DNA/imunologia
Vetores Genéticos/imunologia
Imunidade Inata
Interferon Tipo I/imunologia
Proteínas de Membrana/imunologia
Proteínas Nucleares/imunologia
Nucleotidiltransferases/imunologia
Fosfoproteínas/imunologia
Transdução de Sinais/imunologia
[Mh] Termos MeSH secundário: Animais
Sistemas CRISPR-Cas
Proteínas de Ligação a DNA/genética
Feminino
Técnicas de Silenciamento de Genes
Seres Humanos
Interferon Tipo I/genética
Masculino
Proteínas de Membrana/genética
Camundongos
Camundongos Knockout
Proteínas Nucleares/genética
Nucleotidiltransferases/genética
Fosfoproteínas/genética
Transdução de Sinais/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (AIM2 protein, human); 0 (Aim2 protein, mouse); 0 (DNA-Binding Proteins); 0 (Ifi16 protein, mouse); 0 (Interferon Type I); 0 (MPYS protein, human); 0 (MPYS protein, mouse); 0 (Membrane Proteins); 0 (Nuclear Proteins); 0 (Phosphoproteins); 148998-64-5 (IFI16 protein, human); EC 2.7.7.- (MB21D1 protein, human); EC 2.7.7.- (MB21D1 protein, mouse); EC 2.7.7.- (Nucleotidyltransferases)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170927
[St] Status:MEDLINE
[do] DOI:10.4049/jimmunol.1700698


  2 / 109 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27269055
[Au] Autor:Fougerolle S; Legrand L; Garrett D; Birand I; Foursin M; D'Ablon X; Bayssat P; Newton RJ; Pronost S; Paillot R
[Ad] Endereço:LABÉO-Frank Duncombe, 1 route de Rosel, 14053 CAEN Cedex 4, France; University of Caen Basse-Normandie, 14000 CAEN, France; Unité de Recherche Risques Microbiens (U2RM), EA 4655, and Chair of Excellence «Equine Immunology¼, 14032 CAEN, France; Hippolia Foundation, La Maison du cheval, 6 avenue du Ma
[Ti] Título:Influential factors inducing suboptimal humoral response to vector-based influenza immunisation in Thoroughbred foals.
[So] Source:Vaccine;34(33):3787-95, 2016 Jul 19.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:CONTEXT: Numerous equine influenza (EI) epizooties are reported worldwide. EI vaccination is the most efficient methods of prevention. However, not all horses develop protective immunity after immunisation, increasing the risk of infection and transmission. OBJECTIVES: This field study aimed to understand the poor response to primary EI vaccination. STUDY DESIGN: The EI antibody response was measured in 174 Thoroughbred foals set in 3 stud farms (SF#1 to SF#3) over a 2years period. All foals were immunised with a commercial recombinant canarypox-based EI vaccine. Sera were tested by single radial haemolysis against the A/equine/Jouars/4/06 EIV strain (H3N8) at the time of the first vaccination (V1), 2weeks and 3months after the second immunisation (V2), 2days and 3months after the third immunisation (V3). RESULTS: The frequency of poor-responders (no detectable antibody titres) was surprisingly elevated after V2 (56.8%), increased to 81.7% at V2+3months and reached 98.6% at V3. The frequency of poor-responder was still 19.2%, 3months after V3. Two independent influential factors were identified. The short (V2+2weeks) and mid-term (V2+3months, V3+3months) antibody levels were positively correlated to the age at V1 (p-value=0.003, 0.031 and 0.0038, respectively). Presence of maternally-derived antibodies (MDA) at V1 was negatively correlated with antibody levels after V3 only (p-value=0.0056). Given that SF#1 antibody response was below clinical protective levels at all-time points studied, the annual boost immunisation (V4) was brought forward by 7.0±1.1months. V1 was delayed by 7weeks the following year, which significantly increased short- and mid-term antibody titres (p-value=9.9e-07 and 2.31e-07, respectively). CONCLUSION: The age and MDA at first immunisation with the canarypox-based IE vaccine play an independent role in the establishment of antibody levels. This study also highlights the benefit provided by serological surveillance to evaluate herd immunity and to implement corrective management/vaccination measures.
[Mh] Termos MeSH primário: Doenças dos Cavalos/prevenção & controle
Cavalos/imunologia
Imunidade Humoral
Vacinas contra Influenza/imunologia
Infecções por Orthomyxoviridae/veterinária
[Mh] Termos MeSH secundário: Fatores Etários
Animais
Anticorpos Antivirais/sangue
Formação de Anticorpos
Vírus da Varíola dos Canários
Doenças dos Cavalos/virologia
Imunidade Materno-Adquirida
Vírus da Influenza A Subtipo H3N8
Infecções por Orthomyxoviridae/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Influenza Vaccines)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160609
[St] Status:MEDLINE


  3 / 109 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27013661
[Au] Autor:Li H; Hwang Y; Perry K; Bushman F; Van Duyne GD
[Ad] Endereço:From the Department of Biochemistry & Biophysics, the Graduate Group in Biochemistry and Molecular Biophysics, and.
[Ti] Título:Structure and Metal Binding Properties of a Poxvirus Resolvase.
[So] Source:J Biol Chem;291(21):11094-104, 2016 May 20.
[Is] ISSN:1083-351X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Poxviruses replicate their linear genomes by forming concatemers that must be resolved into monomeric units to produce new virions. A viral resolvase cleaves DNA four-way junctions extruded at the concatemer junctions to produce monomeric genomes. This cleavage reaction is required for viral replication, so the resolvase is an attractive target for small molecule inhibitors. To provide a platform for understanding resolvase mechanism and designing inhibitors, we have determined the crystal structure of the canarypox virus (CPV) resolvase. CPV resolvase is dimer of RNase H superfamily domains related to Escherichia coli RuvC, with an active site lined by highly conserved acidic residues that bind metal ions. There are several intriguing structural differences between resolvase and RuvC, and a model of the CPV resolvase·Holliday junction complex provides insights into the consequences of these differences, including a plausible explanation for the weak sequence specificity exhibited by the poxvirus enzymes. The model also explains why the poxvirus resolvases are more promiscuous than RuvC, cleaving a variety of branched, bulged, and flap-containing substrates. Based on the unique active site structure observed for CPV resolvase, we have carried out a series of experiments to test divalent ion usage and preferences. We find that the two resolvase metal binding sites have different preferences for Mg(2+) versus Mn(2+) Optimal resolvase activity is maintained with 5 µm Mn(2+) and 100 µm Mg(2+), concentrations that are well below those required for either metal alone. Together, our findings provide biochemical insights and structural models that will facilitate studying poxvirus replication and the search for efficient poxvirus inhibitors.
[Mh] Termos MeSH primário: Vírus da Varíola dos Canários/enzimologia
Resolvases de Junção Holliday/química
Resolvases de Junção Holliday/metabolismo
Proteínas Virais/química
Proteínas Virais/metabolismo
[Mh] Termos MeSH secundário: Domínio Catalítico/genética
Cristalografia por Raios X
Endodesoxirribonucleases/química
Endodesoxirribonucleases/metabolismo
Proteínas de Escherichia coli/química
Proteínas de Escherichia coli/metabolismo
Resolvases de Junção Holliday/genética
Magnésio/metabolismo
Manganês/metabolismo
Modelos Moleculares
Mutagênese Sítio-Dirigida
Estrutura Quaternária de Proteína
Proteínas Recombinantes/química
Proteínas Recombinantes/genética
Proteínas Recombinantes/metabolismo
Homologia de Sequência de Aminoácidos
Homologia Estrutural de Proteína
Especificidade por Substrato
Termodinâmica
Proteínas Virais/genética
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Escherichia coli Proteins); 0 (Recombinant Proteins); 0 (Viral Proteins); 0 (ruvC protein, E coli); 42Z2K6ZL8P (Manganese); EC 3.1.- (Endodeoxyribonucleases); EC 3.1.21.- (Holliday Junction Resolvases); I38ZP9992A (Magnesium)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170520
[Lr] Data última revisão:
170520
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160326
[St] Status:MEDLINE
[do] DOI:10.1074/jbc.M115.709139


  4 / 109 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27007879
[Au] Autor:Zanetti FA; Cardona R; Federico CR; Chimeno-Zoth S; Calamante G
[Ad] Endereço:Ciudad Autónoma de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Rivadavia, 1917 (C1033AAJ), Argentina.
[Ti] Título:Recombinant canarypox virus expressing the VP2 protein of infectious bursal disease virus induces protection in vaccinated SPF chickens.
[So] Source:Virol Sin;31(3):266-9, 2016 Jun.
[Is] ISSN:1995-820X
[Cp] País de publicação:China
[La] Idioma:eng
[Mh] Termos MeSH primário: Infecções por Birnaviridae/veterinária
Vírus da Varíola dos Canários/imunologia
Vírus da Doença Infecciosa da Bursa/genética
Doenças das Aves Domésticas/imunologia
Proteínas Estruturais Virais/imunologia
Vacinas Virais/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Neutralizantes/sangue
Anticorpos Antivirais/sangue
Antígenos Virais/genética
Antígenos Virais/imunologia
Infecções por Birnaviridae/imunologia
Infecções por Birnaviridae/prevenção & controle
Bolsa de Fabricius/diagnóstico por imagem
Bolsa de Fabricius/patologia
Vírus da Varíola dos Canários/genética
Vírus da Varíola dos Canários/metabolismo
Galinhas
Vetores Genéticos
Doenças das Aves Domésticas/prevenção & controle
Doenças das Aves Domésticas/virologia
Proteínas Recombinantes/genética
Proteínas Recombinantes/imunologia
Vacinas Sintéticas/administração & dosagem
Vacinas Sintéticas/genética
Vacinas Sintéticas/imunologia
Proteínas Estruturais Virais/biossíntese
Proteínas Estruturais Virais/genética
Vacinas Virais/administração & dosagem
Vacinas Virais/genética
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Antigens, Viral); 0 (Recombinant Proteins); 0 (VP2 protein, infectious bursal disease virus); 0 (Vaccines, Synthetic); 0 (Viral Structural Proteins); 0 (Viral Vaccines)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160324
[St] Status:MEDLINE
[do] DOI:10.1007/s12250-015-3680-6


  5 / 109 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25651753
[Au] Autor:Le Loc'h G; Paul MC; Camus-Bouclainville C; Bertagnoli S
[Ad] Endereço:RENECO Wildlife Consultants LLC, Abu Dhabi, UAE. g.leloch@hotmail.fr.
[Ti] Título:Outbreaks of Pox Disease Due to Canarypox-Like and Fowlpox-Like Viruses in Large-Scale Houbara Bustard Captive-Breeding Programmes, in Morocco and the United Arab Emirates.
[So] Source:Transbound Emerg Dis;63(6):e187-e196, 2016 Dec.
[Is] ISSN:1865-1682
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Infectious diseases can be serious threats for the success of reinforcement programmes of endangered species. Houbara Bustard species (Chlamydotis undulata and Chlamydotis macqueenii), whose populations declined in the last decades, have been captive-bred for conservation purposes for more than 15 years in North Africa and the Middle East. Field observations show that pox disease, caused by avipoxviruses (APV), regularly emerges in conservation projects of Houbara Bustard, despite a very strict implementation of both vaccination and biosecurity. Data collected from captive flocks of Houbara Bustard in Morocco from 2006 through 2013 and in the United Arab Emirates from 2011 through 2013 were analysed, and molecular investigations were carried out to define the virus strains involved. Pox cases (n = 2311) were observed during more than half of the year (88% of the months in Morocco, 54% in the United Arab Emirates). Monthly morbidity rates showed strong variations across the time periods considered, species and study sites: Four outbreaks were described during the study period on both sites. Molecular typing revealed that infections were mostly due to canarypox-like viruses in Morocco while fowlpox-like viruses were predominant in the United Arab Emirates. This study highlights that APV remain a major threat to consider in bird conservation initiatives.
[Mh] Termos MeSH primário: Vírus da Varíola dos Canários/isolamento & purificação
Surtos de Doenças/veterinária
Vírus da Varíola das Aves Domésticas/isolamento & purificação
Varíola Aviária/epidemiologia
Infecções por Poxviridae/veterinária
Vacinação/veterinária
[Mh] Termos MeSH secundário: Animais
Aves
Cruzamento
Vírus da Varíola dos Canários/genética
Conservação dos Recursos Naturais
Feminino
Varíola Aviária/mortalidade
Varíola Aviária/virologia
Vírus da Varíola das Aves Domésticas/genética
Masculino
Marrocos/epidemiologia
Infecções por Poxviridae/epidemiologia
Infecções por Poxviridae/mortalidade
Infecções por Poxviridae/virologia
Emirados Árabes Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170130
[Lr] Data última revisão:
170130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150206
[St] Status:MEDLINE
[do] DOI:10.1111/tbed.12330


  6 / 109 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26604264
[Au] Autor:Poulet H; Thibault JC; Masias A
[Ad] Endereço:Merial, R&D, Lyon Gerland Laboratories, Lyon, France herve.poulet@merial.com.
[Ti] Título:Immunosuppression in a Comparative Study of Feline Leukemia Virus Vaccines.
[So] Source:Clin Vaccine Immunol;22(12):1294-5, 2015 Dec.
[Is] ISSN:1556-679X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Vírus da Varíola dos Canários/genética
Doenças do Gato/prevenção & controle
Doenças do Gato/virologia
Vírus da Leucemia Felina/imunologia
Infecções por Retroviridae/veterinária
Infecções Tumorais por Vírus/veterinária
Vacinas Virais/imunologia
[Mh] Termos MeSH secundário: Animais
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Viral Vaccines)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:151214
[Lr] Data última revisão:
151214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151126
[St] Status:MEDLINE
[do] DOI:10.1128/CVI.00497-15


  7 / 109 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26604265
[Au] Autor:Patel M; Carritt K; Lane J; Jayappa H; Stahl M; Bourgeois M
[Ad] Endereço:Merck Animal Health, Elkhorn, Nebraska, USA.
[Ti] Título:Reply to "Immunosuppression in a Comparative Study of Feline Leukemia Virus Vaccines".
[So] Source:Clin Vaccine Immunol;22(12):1296-7, 2015 Dec.
[Is] ISSN:1556-679X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Vírus da Varíola dos Canários/genética
Doenças do Gato/prevenção & controle
Doenças do Gato/virologia
Vírus da Leucemia Felina/imunologia
Infecções por Retroviridae/veterinária
Infecções Tumorais por Vírus/veterinária
Vacinas Virais/imunologia
[Mh] Termos MeSH secundário: Animais
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Viral Vaccines)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:160601
[Lr] Data última revisão:
160601
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151126
[St] Status:MEDLINE
[do] DOI:10.1128/CVI.00504-15


  8 / 109 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25972402
[Au] Autor:Patel M; Carritt K; Lane J; Jayappa H; Stahl M; Bourgeois M
[Ad] Endereço:Merck Animal Health, Elkhorn, Nebraska, USA.
[Ti] Título:Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression.
[So] Source:Clin Vaccine Immunol;22(7):798-805, 2015 Jul.
[Is] ISSN:1556-679X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Four vaccines for feline leukemia virus (FeLV) are available in the United States. This study's purpose was to compare the efficacy of Nobivac feline 2-FeLV (an inactivated, adjuvanted whole-virus vaccine) and PureVax recombinant FeLV (a live, canarypox virus-vectored vaccine) following FeLV challenge. Cats were vaccinated at 9 and 12 weeks with Nobivac feline 2-FeLV (group A, n = 11) or PureVax recombinant FeLV (group B, n = 10). Group C (n = 11) comprised unvaccinated controls. At 3 months postvaccination, cats were immunosuppressed and challenged with FeLV-A/61E. The outcomes measured were persistent antigenemia at 12 weeks postchallenge (PC) and proviral DNA and viral RNA at 3 to 9 weeks PC. Persistent antigenemia was observed in 0 of 11 cats in group A, 5 of 10 cats in group B, and 10 of 11 cats in group C. Group A was significantly protected compared to those in groups B (P < 0.013) and C (P < 0.0001). No difference was found between groups B and C (P > 0.063). The preventable fraction was 100% for group A and 45% for group B. At 9 weeks PC, proviral DNA and viral RNA were detected 1 of 11 cats in group A, 6 of 10 cats in group B, and 9 of 11 cats in group C. Nucleic acid loads were significantly lower in group A than in group C (P < 0.01). Group A had significantly lower proviral DNA loads than group B at weeks 6 to 9 (P < 0.02). The viral RNA loads were significantly lower in group A than in group B at weeks 7 to 9 (P < 0.01). The results demonstrate that Nobivac feline 2-FeLV-vaccinated cats were fully protected against persistent antigenemia and had significantly smaller amounts of proviral DNA and plasma viral RNA loads than PureVax recombinant FeLV-vaccinated cats and unvaccinated controls.
[Mh] Termos MeSH primário: Vírus da Varíola dos Canários/genética
Doenças do Gato/prevenção & controle
Doenças do Gato/virologia
Vírus da Leucemia Felina/imunologia
Infecções por Retroviridae/veterinária
Infecções Tumorais por Vírus/veterinária
Vacinas Virais/imunologia
[Mh] Termos MeSH secundário: Animais
Antígenos Virais/sangue
Gatos
DNA Viral/sangue
Portadores de Fármacos
RNA Viral/sangue
Infecções por Retroviridae/prevenção & controle
Infecções por Retroviridae/virologia
Resultado do Tratamento
Infecções Tumorais por Vírus/prevenção & controle
Infecções Tumorais por Vírus/virologia
Estados Unidos
Vacinas de Produtos Inativados/administração & dosagem
Vacinas de Produtos Inativados/imunologia
Vacinas Sintéticas/administração & dosagem
Vacinas Sintéticas/imunologia
Carga Viral
Vacinas Virais/administração & dosagem
Viremia/prevenção & controle
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antigens, Viral); 0 (DNA, Viral); 0 (Drug Carriers); 0 (RNA, Viral); 0 (Vaccines, Inactivated); 0 (Vaccines, Synthetic); 0 (Viral Vaccines)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150515
[St] Status:MEDLINE
[do] DOI:10.1128/CVI.00034-15


  9 / 109 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25092462
[Au] Autor:Bareiss B; Barry M
[Ad] Endereço:Li Ka Shing Institute of Virology, 621 HMRC, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton Alberta, Canada, T6G 2S2.
[Ti] Título:Fowlpox virus encodes two p28-like ubiquitin ligases that are expressed early and late during infection.
[So] Source:Virology;462-463:60-70, 2014 Aug.
[Is] ISSN:1096-0341
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Many cellular processes are regulated by the ubiquitin-proteasome system. Therefore, it is not surprising that viruses have adapted ways to manipulate the ubiquitin-proteasome system to their own advantage. p28 is a poxvirus encoded ubiquitin ligase that contains an N-terminal KilA-N DNA binding domain and a C-terminal RING domain required for ubiquitin ligase activity. p28 is encoded by a wide range of poxviruses, including members of the Avipoxviruses. Here we show that fowlpox virus (FWPV) and canarypox virus (CNPV) each contain two distinct p28-like ubiquitin ligases; an observation not seen in other members of the poxvirus family. FWPV150 and FWPV157 are both ubiquitinated during infection and co-localize with conjugated ubiquitin at the viral factory. Interestingly, we demonstrate that FWPV150 was actively transcribed early, while FWPV157 was expressed late. Overall, these observations suggest different temporal roles for FWPV150 and FWPV157, an observation unique to the Avipoxviruses.
[Mh] Termos MeSH primário: Vírus da Varíola dos Canários/enzimologia
Vírus da Varíola dos Canários/genética
Vírus da Varíola das Aves Domésticas/enzimologia
Vírus da Varíola das Aves Domésticas/genética
Regulação Viral da Expressão Gênica
Ubiquitina-Proteína Ligases/biossíntese
Ubiquitina-Proteína Ligases/genética
[Mh] Termos MeSH secundário: Animais
Linhagem Celular
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
EC 2.3.2.27 (Ubiquitin-Protein Ligases)
[Em] Mês de entrada:1409
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140806
[St] Status:MEDLINE


  10 / 109 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:25000692
[Au] Autor:Marrow JC; Padilla LR; Hayek LA; Bush M; Murray S
[Ti] Título:Comparison of antibody response to a non-adjuvanted, live canarypox-vectored recombinant rabies vaccine and a killed, adjuvanted rabies vaccine in Eld's deer (Rucervus eldi thamin).
[So] Source:J Zoo Wildl Med;45(2):315-20, 2014 Jun.
[Is] ISSN:1042-7260
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Captive Eld's deer (Rucervus eldi thamin) were evaluated for the presence of rabies virus-neutralizing antibodies using a rapid fluorescent focus inhibition after vaccination with either a live canarypox-vectored recombinant rabies vaccine or a killed monovalent rabies vaccine. Twelve deer were vaccinated with 1.0 ml of killed, adjuvanted, monovalent rabies vaccine at 5-33 mo of age then annually thereafter, and 14 deer were vaccinated with 1.0 ml nonadjuvanted, live canarypox-vectored rabies vaccine at 3-15 mo of age then annually thereafter. Banked serum was available or collected prospectively from deer at 6 mo and 1 yr after initial vaccination, then collected annually. Rabies virus-neutralizing antibodies considered adequate (>0.5 IU/ml) were present in 20/34 samples vaccinated with canarypox-vectored rabies vaccine and in 12/14 samples vaccinated with killed adjuvanted rabies vaccine. Poor seroconversion was noted in deer less than 6 mo of age vaccinated with the canarypox-vectored rabies vaccine.
[Mh] Termos MeSH primário: Anticorpos Antivirais/sangue
Vírus da Varíola dos Canários/fisiologia
Cervos/sangue
Vacinas Antirrábicas/imunologia
Raiva/veterinária
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos
Animais
Feminino
Vetores Genéticos
Masculino
Estudos Prospectivos
Raiva/prevenção & controle
Vírus da Raiva/genética
Vírus da Raiva/imunologia
Proteínas Recombinantes
Vacinação/métodos
Vacinas Sintéticas/genética
Proteínas Virais
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Antibodies, Viral); 0 (Rabies Vaccines); 0 (Recombinant Proteins); 0 (Vaccines, Synthetic); 0 (Viral Proteins)
[Em] Mês de entrada:1407
[Cu] Atualização por classe:140708
[Lr] Data última revisão:
140708
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140709
[St] Status:MEDLINE



página 1 de 11 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde